Suraksha Diagnostic Ltd

The transcript from the Suraksha Diagnostic Limited Q3 & 9M FY'26 Earnings Call does not mention any current or planned future fundraising through debt or equity. Specific points on fundraising are absent, indicating: - No explicit discussion on raising capital via debt or equity in the given excerpts. - The company is focusing on expansion primarily through internal accruals and targeted capex (INR 70 crores annually for 12-15 centers). - Strategic growth emphasis is on scaling existing operations and expanding into new geographies like Northeast India, Bihar, and Jharkhand, rather than seeking external fundraising. - No indications of immediate plans for fundraising were provided during the Q&A or management remarks. Hence, based on the available data, Suraksha Diagnostic Limited has not disclosed any current or future fundraising plans through debt or equity.

- Suraksha Diagnostic Limited plans to open 12 to 15 new centers annually with a consistent capex of around INR 70 crores per year (Page 12). - For FY’27, the company targets adding five large hub centers and 10 small centers with similar capex (~INR 70 crore) as prior years (Page 12). - In Q4 FY’26, six centers are under development: three big centers, one PPP center, and two small centers; 60-70% expected operational in Q4 with possible spillover into next FY (Page 14). - The company is cautious with PPP centers due to low margins and receivable issues, preferring to deploy capital in other center types (Page 8 & 13). - No increase in capex is anticipated for FY’27 beyond 70 crores; focus remains on expansion and scaling existing business (Page 12).

- Q3 FY’26 revenue grew 30% YoY, driven by volume expansion and genomics product mix. - Number of patients served increased by 23% YoY in Q3 FY’26. - Number of tests performed grew 30.7% YoY in Q3 FY’26. - Genomics segment showing strong growth: INR2.1-2.2 million monthly run rate and expected to scale further. - Target to add 12-15 new centers annually, including six centers planned for Q4 FY’26 (3 big, 1 PPP, 2 small). - Expansion into new geographies like Northeast India, Bihar, and Jharkhand is planned. - Revenue per patient expected to grow with addition of high-value tests, especially genomics. - No general price hikes expected, but incremental pricing on new tests planned. - Long-term scale expected to improve margins as new centers mature. - Target to reach 100 centers by FY’28, indicating strong growth focus.

- Suraksha Diagnostic Limited expects strong topline momentum with 30% YoY revenue growth in Q3 FY’26 driven by volume expansion and product mix including genomics. - EBITDA margins may see a temporary compression (around 32% in FY’26) due to pre-operative costs for new centers but are expected to improve by FY’27 Q3 as new centers mature and economies of scale set in. - The company plans to add 12-15 centers annually, targeting 100 centers by FY’28, supporting long-term revenue growth and scale. - Genomics segment, currently nascent, is expected to grow significantly and become a major growth driver by FY’28. - New geography expansion, including Northeast and Bihar, is expected to replicate revenue per patient levels similar to Kolkata. - Long-term EBITDA margins are anticipated to revert to higher levels with efficient mature centers and cost management. - PAT margin remained stable with growth from 9.3% in Q3 FY’26; future improvements expected with scale.

The transcript does not explicitly mention the current or expected order book or pending orders for Suraksha Diagnostic Limited. However, some relevant points about ongoing projects and expansions include: - Six centers are under development for Q4 FY’26: 3 large centers, 1 PPP center, and 2 small centers. - Expected to operationalize around 60-70% of these centers by Q4 FY’26; 1-2 centers may spill into the next financial year. - Targeting to reach 100 centers by FY’28. - Plan to add 12 to 15 centers annually with a capex of around INR 70 crores. - Expansion into new geographies like Northeast India, Bihar, and Jharkhand is planned for the next financial year. No specific order backlog or pending contractual orders are disclosed in the transcript.